Trial Profile
A Phase II Trial of LEE011 in Combination With Everolimus in the Treatment of Advanced Well Differentiated Neuroendocrine Tumors of Foregut Origin
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Feb 2024
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Ribociclib (Primary)
- Indications Bronchial cancer; Duodenal cancer; Gastric cancer; Lung cancer; Malignant thymoma; Neuroendocrine tumours; Pancreatic cancer
- Focus Therapeutic Use
- 01 Feb 2024 Status changed from active, no longer recruiting to completed.
- 22 Feb 2023 Planned End Date changed from 1 Feb 2023 to 1 Feb 2024.
- 22 Feb 2023 Planned primary completion date changed from 1 Feb 2023 to 1 Feb 2024.